Abstract
Prostate cancer (PCa) is one of the most common malignancies for males, but very little is known about its pathogenesis. This study aimed to identify novel biomarkers associated with PCa prognosis and elucidate the underlying molecular mechanism. First, The Cancer Genome Atlas (TCGA) RNA-sequencing data were utilized to identify differentially expressed genes (DEGs) between tumor and normal samples. The DEGs were then applied to construct a co-expression and mined using structure network analysis. The magenta module that was highly related to the Gleason score (r = 0.46, p = 3e–26) and tumor stage (r = 0.38, p = 2e–17) was screened. Subsequently, all genes of the magenta module underwent function annotation. From the key module, CCNA2, CKAP2L, NCAPG, and NUSAP1 were chosen as the four candidate genes. Finally, internal (TCGA) and external data sets (GSE32571, GSE70770, and GSE141551) were combined to validate and predict the value of real hub genes. The results show that the above genes are up-regulated in PCa samples, and higher expression levels show significant association with higher Gleason scores and tumor T stage. Moreover, receiver operating characteristic curve and survival analysis validate the excellent value of hub genes in PCa progression and prognosis. In addition, the protein levels of these four genes also remain higher in tumor tissues when compared with normal tissues. Gene set enrichment analysis and gene set variation analysis for a single gene reveal the close relation with cell proliferation. Meanwhile, 11 small molecular drugs that have the potential to treat PCa were also screened. In conclusion, our research identified four potential prognostic genes and several candidate molecular drugs for treating PCa.
Highlights
Prostate cancer (PCa) is the second most frequent malignancy and the fifth leading cause of death in males throughout the world (Bray et al, 2018)
The RNA-seq data of 498 tumor samples and 52 normal samples obtained from the The Cancer Genome Atlas (TCGA) data set underwent differentially expressed genes (DEGs) analysis by three algorithms: limma (Ritchie et al, 2015), DESeq2 (Love et al, 2014), and edgeR (Robinson et al, 2009)
Using the cutoff criteria of adj.p.value of
Summary
Prostate cancer (PCa) is the second most frequent malignancy and the fifth leading cause of death in males throughout the world (Bray et al, 2018). Prostate biopsy has become the standard for diagnosing PCa worldwide. Prostate-specific antigens (PSA) are considered a reliable prostate tumor marker, especially in the early stages of PCa. Despite the wide use of PSA tests in screening for PCa, this approach has some restrictions. In several non-malignant cases, such as those with prostatitis and benign prostatic hyperplasia, serum PSA frequently increases, affecting the accuracy of the PSA test (McDonald et al, 2014).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.